{
    "ticker": "CDNA",
    "name": "CareDx, Inc.",
    "description": "CareDx, Inc. is a leading provider of transplant diagnostic solutions aimed at improving the quality of life for transplant patients. Founded in 1998 and headquartered in Brisbane, California, CareDx specializes in developing and commercializing innovative genomic-based solutions for organ transplant patients. The company's flagship product, AlloSure, is a non-invasive, blood-based test that assesses kidney transplant rejection through the measurement of donor-derived cell-free DNA. This groundbreaking technology allows for earlier detection of potential transplant rejection, enabling physicians to make informed decisions about patient care. In addition to AlloSure, CareDx offers a comprehensive suite of diagnostic tools, including AlloMap, which assesses heart transplant rejection, and AlloSeq, a platform for genomic profiling. The company is committed to advancing the field of transplant medicine through research, education, and partnerships with transplant centers worldwide. With a focus on precision medicine, CareDx continues to innovate and expand its product offerings to address the evolving needs of transplant patients and healthcare providers. The company\u2019s mission is to provide personalized and timely solutions that support the transplant community in improving patient outcomes and enhancing the overall quality of care.",
    "industry": [
        "Healthcare",
        "Diagnostics"
    ],
    "headquarters": "Brisbane, California, USA",
    "founded": "1998",
    "website": "https://www.caredx.com",
    "ceo": "Harlan W. Weisman",
    "social_media": {
        "twitter": "https://twitter.com/CareDx",
        "linkedin": "https://www.linkedin.com/company/caredx/"
    },
    "investor_relations": "https://investors.caredx.com",
    "key_executives": [
        {
            "name": "Harlan W. Weisman",
            "position": "CEO"
        },
        {
            "name": "Michael D. Bell",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Transplant Diagnostics",
            "products": [
                "AlloSure",
                "AlloMap",
                "AlloSeq"
            ]
        }
    ],
    "seo": {
        "meta_title": "CareDx, Inc. | Leading Transplant Diagnostic Solutions",
        "meta_description": "Discover CareDx, Inc., a pioneer in transplant diagnostics. Explore innovative genomic solutions for organ transplant patients and improve patient outcomes.",
        "keywords": [
            "CareDx",
            "Transplant Diagnostics",
            "AlloSure",
            "Genomic Solutions",
            "Organ Transplant"
        ]
    },
    "faq": [
        {
            "question": "What is CareDx known for?",
            "answer": "CareDx is known for its innovative transplant diagnostic solutions, including blood-based tests for organ transplant rejection."
        },
        {
            "question": "Who is the CEO of CareDx?",
            "answer": "Harlan W. Weisman is the CEO of CareDx, Inc."
        },
        {
            "question": "Where is CareDx headquartered?",
            "answer": "CareDx is headquartered in Brisbane, California, USA."
        },
        {
            "question": "What are CareDx's main products?",
            "answer": "CareDx's main products include AlloSure, AlloMap, and AlloSeq."
        },
        {
            "question": "When was CareDx founded?",
            "answer": "CareDx was founded in 1998."
        }
    ],
    "competitors": [
        "NVTA",
        "NTRA",
        "GENE"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "ILMN",
        "ABT"
    ]
}